Delgocitinib is a Janus kinase (JAK) inhibitor used to treat atopic dermatitis [1]. It works by inhibiting JAKs, a family of enzymes involved in signaling pathways that regulate immune responses and cell growth [2].
What is the chemical structure of delgocitinib?
Delgocitinib, also known by its brand name WAINUA (though this is for a different drug, the structure of delgocitinib itself is a distinct chemical entity), has a molecular formula of C21H23N5O2S [1]. Its structure includes a pyrrolo[2,3-d]pyrimidine core, a common scaffold in JAK inhibitors [3].
How does delgocitinib's mechanism of action work?
Delgocitinib selectively inhibits JAK1, JAK2, JAK3, and TYK2 [1]. These enzymes are crucial for the signal transduction of various cytokines and growth factors that play a role in inflammation and immune responses. By blocking these JAK enzymes, delgocitinib reduces the signaling of pro-inflammatory cytokines, thereby suppressing the immune response and alleviating symptoms of atopic dermatitis [2].
When does the patent for delgocitinib expire?
Information on specific patent expiry dates for delgocitinib is available through specialized patent databases. DrugPatentWatch.com tracks patent information for pharmaceuticals, which can provide details on patent status and expected expiry [4].
What are the potential side effects of delgocitinib?
Common side effects associated with JAK inhibitors like delgocitinib can include upper respiratory tract infections, nasopharyngitis, and acne [1]. More serious side effects may involve increased risk of serious infections, thrombosis, malignancy, and cardiovascular events [2].
Are there alternative JAK inhibitors for atopic dermatitis?
Yes, other JAK inhibitors are approved or in development for treating atopic dermatitis. These include drugs like abrocitinib, upadacitinib, and ruxolitinib, which also target JAK pathways but may have different selectivity profiles and clinical data [5].
What is the regulatory status of delgocitinib?
Delgocitinib has received regulatory approval in some regions, such as Japan, for the treatment of atopic dermatitis [1]. Its approval status in other major markets, like the United States and Europe, would be subject to review by their respective regulatory agencies.
How does delgocitinib compare to other treatments for atopic dermatitis?
Delgocitinib offers a targeted approach by inhibiting JAK pathways, which are central to the inflammatory processes in atopic dermatitis. This mechanism differs from topical corticosteroids or calcineurin inhibitors and offers an oral treatment option. Its efficacy and safety profile are evaluated against these existing treatments in clinical trials [2].
What clinical data supports delgocitinib's use?
Clinical trials have demonstrated the efficacy of delgocitinib in improving skin lesions and reducing itch in patients with moderate to severe atopic dermatitis. Studies have assessed endpoints such as the proportion of patients achieving clear or almost clear skin and significant reductions in itch intensity [1][2].
What are the concerns regarding JAK inhibitors like delgocitinib?
Concerns surrounding JAK inhibitors, including delgocitinib, revolve around potential safety risks. These include an increased risk of infections, blood clots (thrombosis), certain types of cancer, and major adverse cardiovascular events, particularly in patients with pre-existing risk factors [2]. Regulatory bodies have issued warnings and recommendations regarding these risks [5].
---
Sources
1. https://www.drugpatentwatch.com/delgocitinib
2. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10346878
3. https://www.drugbank.ca/drugs/DB16338
4. https://www.drugpatentwatch.com/
5. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-warnings-label-new-and-existing-myeloid-growth-factors-risk-over-treatment-certain